The report provides comprehensive information on the
therapeutics under development for Elephantiasis
(Lymphatic Filariasis), complete with analysis by stage of development, drug
target, mechanism of action (MoA), route of administration (RoA) and molecule
type. The report also covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest news and
press releases. Additionally, the report provides an overview of key players
involved in therapeutic development for Elephantiasis (Lymphatic Filariasis)
and features dormant and discontinued projects.
Get Sample Report @ https://www.wiseguyreports.com/sample-request/619248-elephantiasis-lymphatic-filariasis-pipeline-review-h2-2016
Report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. Drug profiles
featured in the report undergoes periodic review following a stringent set of
processes to ensure that all the profiles are updated with the latest set of
information. Additionally, various dynamic tracking processes ensure that the
most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging
players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic
landscape of Elephantiasis (Lymphatic Filariasis)
- The report reviews pipeline therapeutics for Elephantiasis
(Lymphatic Filariasis) by companies and universities/research institutes based
on information derived from company and industry-specific sources
- The report covers pipeline products based on various
stages of development ranging from pre-registration till discovery and
undisclosed stages
- The report features descriptive drug profiles for the
pipeline products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Elephantiasis (Lymphatic
Filariasis) therapeutics and enlists all their major and minor projects
- The report assesses Elephantiasis (Lymphatic Filariasis)
therapeutics based on drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued
pipeline projects
- The report reviews latest news related to pipeline
therapeutics for Elephantiasis (Lymphatic Filariasis)
Reasons to buy
- Gain strategically significant competitor information,
analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of
therapeutics under development for Elephantiasis (Lymphatic Filariasis)
- Identify potential new clients or partners in the target
demographic
- Develop strategic initiatives by understanding the focus
areas of leading companies
- Plan mergers and acquisitions effectively by identifying
key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by
understanding Elephantiasis (Lymphatic Filariasis) pipeline depth and focus of
Indication therapeutics
- Develop and design in-licensing and out-licensing
strategies by identifying prospective partners with the most attractive
projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying
discontinued projects and understanding the factors that drove them from
pipeline
Table of
Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Elephantiasis (Lymphatic Filariasis) Overview 6
Therapeutics Development 7
Pipeline Products for Elephantiasis (Lymphatic Filariasis) -
Overview 7
Pipeline Products for Elephantiasis (Lymphatic Filariasis) -
Comparative Analysis 8
Elephantiasis (Lymphatic Filariasis) - Therapeutics under
Development by Companies 9
Elephantiasis (Lymphatic Filariasis) - Therapeutics under
Investigation by Universities/Institutes 10
Elephantiasis (Lymphatic Filariasis) - Pipeline Products
Glance 11
Clinical Stage Products 11
Early Stage Products 12
Elephantiasis (Lymphatic Filariasis) - Products under
Development by Companies 13
Elephantiasis (Lymphatic Filariasis) - Products under
Investigation by Universities/Institutes 14
Elephantiasis (Lymphatic Filariasis) - Companies Involved in
Therapeutics Development 15
Eisai Co., Ltd. 15
Johnson & Johnson 16
Elephantiasis (Lymphatic Filariasis) - Therapeutics
Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 21
Drug Profiles 23
EDE-1206 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
filariasis vaccine - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
flubendazole - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
IIC-950A001 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
lymphatic filariasis vaccine - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
S-0112091 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Small Molecules for Lymphatic Filariasis and Onchocerciasis
- Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Access Report @ https://www.wiseguyreports.com/reports/619248-elephantiasis-lymphatic-filariasis-pipeline-review-h2-2016
Contact Info:
NORAH TRENT
Partner Relations
& Marketing Manager
Ph:
+1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get
in touch:
LinkedIn:
www.linkedin.com/company/4828928
Twitter:
https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
No comments:
Post a Comment